Perspectives on Outsourcing

Growth is seen in outsourcing of insect- and plant-cell-based bioproduction expression systems.

Is the contract-only CMO an endangered species?

Will international biomanufacturing outsourcing become mainstream in this decade?

The procurement organization rethinks sourcing for maximum efficiency and results.

Measuring the size of the market for contract manufacturing services requires a careful hand.

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

Budgets for biopharma activities are gaining in select functional areas, except outsourcing.

Industry wants more innovation, but can suppliers meet customers' needs?

Service providers must focus on delivering a superior customer experience.

Recovery audits and other best practices in procurement can improve the bottom line.

The evolving bio/pharmaceutical business model poses risk for CMOs.

Industry optimism is on the rise for 2012.

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.

China rises to the top as a destination for international outsourcing.

Better strategies and practices in sourcing and procurement can contribute to the bottom line.

A recent industry survey shows keen interest in improving bioreactors and cell-culture media.

Addressing supply-chain challenges.

Mergers and acquisitions expected to increase, as big companies bolster piplines by acquiring smaller biotech companies.

Indian manufacturers are not now a threat to Western CMOs, but may be long term.

CDMOs and CMOs face weak economic recovery, consolidation, and globalization.

Covance's deal with Sanofi-Aventis demonstrates the power of scale and scope.

Venture capital is still scarce for early biotechs and their providers.

How current economic conditions affect your build-or-buy decision.